Home Biosimilar Antibodies Transmembrane Transporters Sodium Channel antibody Lifastuzumab (Anti-SLC34A2) For research use only.
Not for use in humans.

Lifastuzumab (Anti-SLC34A2)

Synonyms: null

Lifastuzumab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. MW : 145.5 KD.

Lifastuzumab (Anti-SLC34A2)

Purity & Quality Control

Batch: A235001 Purity: 99% Protein concentration: 9.85mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective Sodium Channel Inhibitors

Name Citation Sodium Channel Others
A-803467 2
Camostat Mesilate 16
Ambroxol HCl 0
Flecainide hydrochloride 0
Suzetrigine 0
Tenapanor 0
SEA0400 0 ROS,ERK,p38 MAPK
SLC13A5-IN-1 0
LTGO-33
EIPA
Vernakalant (RSD1235) Hydrochloride
QX-314 chloride
VX-150
Rimeporide
(-)-Sparteine Sulfate
Benzocaine
Tolperisone HCl
Vinpocetine
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Lifastuzumab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. MW : 145.5 KD.

Product Details

CAS No. 1615697-16-9
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lifastuzumab (Anti-SLC34A2) | Lifastuzumab (Anti-SLC34A2) supplier | purchase Lifastuzumab (Anti-SLC34A2) | Lifastuzumab (Anti-SLC34A2) cost | Lifastuzumab (Anti-SLC34A2) manufacturer | order Lifastuzumab (Anti-SLC34A2) | Lifastuzumab (Anti-SLC34A2) distributor